Results 41 to 50 of about 5,785,217 (307)

Patient reported outcomes in view of symptom experience of late effects and self-management of adult long-term survivors after allogeneic haematopoietic stem cell transplantation - a mixed methods study [PDF]

, 2014
Even years after allogeneic stem cell transplantation, recipients face a continuing risk of developing serious late effects. Previous studies have focused on the pathophysiological understanding of late effects, as well as on treatment and disease ...
Kirsch, Monika
core   +1 more source

Do high-volume centers really save more lives? A call for scientific rigor and transparency. Response to Comment on: Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy

Haematologica
Not available.
Wolfgang Bethge, Peter Dreger, German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy e.V. (DAG-HSZT) - German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)   +2 more
doaj   +1 more source

Thymopoiesis in Pre- and Post-Hematopoietic Stem Cell Transplantation

Frontiers in Immunology, 2018
Hematopoietic stem cell transplantation (HSCT) is an important therapeutic option for some hematological diseases. However, patients who undergo HSCT acquire a state of immunodeficiency that causes significant mortality. Reconstitution of thymic function
Luis Klaus A. da Rocha, Samar Freschi de Barros, Francine Bandeira, Alexia Bollini, Lucia Helena de A. Testa, Anderson João Simione, Marina de O. e Souza, Lilian P. Zanetti, Leila Cibele S. de Oliveira, Ana Claúdia F. dos Santos, Mair Pedro de Souza, Vergílio Antônio R. Colturado, Jorge Kalil, Clarisse M. Machado, Luiza Guilherme   +14 more
doaj   +1 more source

Novel_circ_003686 regulates the osteogenic differentiation of MSCs in patients with myeloma bone disease through miR-142-5p/IGF1 axis

Journal of Bone Oncology, 2023
Objectives: Circ_003686 is a novel_circRNA with abnormally low expression found in the samples of multiple myeloma bone disease (MBD) patients. The current research intended to investigate the effects of novel_circ_003686 in osteogenesis-induced ...
Ling Qiu, Lei Ma, Dan Chen, Nan Zhang, Jiao Cai, Qian Zhang, Xiao Wang, Hai Yi, Hao Yao, Fang-Yi Fan   +9 more
doaj   +1 more source

Hematopoietic stem cell transplantation in Oman [PDF]

Bone Marrow Transplantation, 2008
Hematopoietic SCT (HSCT) is an integral part of the management of patients with hematologic disorders. The Sultanate of Oman, with a population of 2.3 million, has an HSCT program based in the Sultan Qaboos University (SQU) hospital. Initiated in 1995, this two-bed unit continues to be the only program in the country. Between June 1995 and August 2006,
D, Dennison, S, Al Kindi, A, Pathare, S, Daar, N, Nusrat, J, Ur Rehman, F, Zia, H, Khan, M Irfan, Khan, A, Alghazaly, S, Al Zadjali, M, Tauro, At, Al Lawatia, Ss, Ganguly   +13 more
openaire   +2 more sources

Comparison between different reduced intensity conditioning regimens in AML/MDS patients in a Latin American center of adult stem cell transplantation

Hematology
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for several hematological diseases. Prospective and retrospective studies have associated myeloablative conditioning regimens with increased non-relapse ...
José Salinas, Yorman Flores, Patricio Rojas, Catherine Gutierrez, Marcela Vidal, Verónica Jara, James Campbell, María José García, Vicente Sandoval, Maximiliano Vergara, Mauricio Ocqueteau, Felipe Palacios, Mauricio Sarmiento   +12 more
doaj   +1 more source

Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial

Frontiers in Oncology, 2023
BackgroundRefractory/relapsed acute myeloid leukemia (R/R AML) has unsatisfactory outcomes even after allogeneic hematopoietic stem cell transplantation.
Chengtao Zhang, Da Gao, Xiaohong Wang, Xiuli Sun, Yan Yan, Yan Yang, Jingjing Zhang, Jinsong Yan, Jinsong Yan, Jinsong Yan   +9 more
doaj   +1 more source

EDTA‐induced pseudothrombocytopenia in hematopoietic stem cell donor

Clinical Case Reports, 2023
We herein report a case of peripheral blood stem cell transplantation (PBSCT) involving a donor with EDTA‐induced pseudothrombocytopenia (PTCP). The apheresis product was inspected for 24 h and there was no platelet clumping or thrombocytopenia.
Misato Tsubokura, Minoru Kojima, Saori Nakabayashi, Noriko Takahashi, Sayaka Takeuchi, Yu Aruga, Chiaki Ikeda, Naoki Maezawa, Koji Okazaki, Sanshiro Uchida, Mizuki Watanabe, Jun Aoki, Ayumu Ito, Takashi Tanaka, Yoshihiro Inamoto, Sung‐Won Kim, Hiromichi Matsushita, Takahiro Fukuda   +17 more
doaj   +1 more source

Post-stem cell transplant maintenance for pediatric acute leukemias: insights from a Brazilian institution with a Latin American perspective

Frontiers in Oncology
IntroductionIn resource-limited countries, access to advanced therapies like CAR T-cell therapy is often unattainable. Clinical trials face challenges, with pediatric populations frequently excluded or experiencing significant delays. This highlights the
Carla Nolasco Monteiro Breviglieri, Roseane Vasconcelos Gouveia, Roseane Vasconcelos Gouveia, Valéria Cortez Ginani, Valéria Cortez Ginani, Camila Noronha Santos, Milena Reis Santos de Oliveira, Anna Beatriz Willemes Batalha, Gabriella Sayuri de Alencar, Edna Harumi Goto, Juliana Francielle Marques, Marcia Puato Vieira Pupim, Adriana Seber, Adriana Seber   +13 more
doaj   +1 more source

A survey on cellular and engineered tissue therapies in Europe in 2008 [PDF]

, 2010
Cellular therapy is an evolving investigational treatment modality in regenerative medicine, but little published information is available on its current use.
Martin, Ivan, Niederwieser, Dietger, Gratwohl, Alois, Baldomero, Helen, Tyndall, Alan   +4 more
core   +1 more source